Jean Bergeron Selected Research

Therapeutics

1/2024	Sex differences in the presentation, treatment and outcomes of patients with homozygous familial hypercholesterolemia.
12/2023	Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study.
6/2022	Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study.
11/2019	Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin.
10/2019	The Lifelong Burden of Homozygous Familial Hypercholesterolemia.
1/2017	Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment.
8/2016	Comparison of two low-density lipoprotein apheresis systems in patients with homozygous familial hypercholesterolemia.
3/2005	Contribution of abdominal visceral obesity and insulin resistance to the cardiovascular risk profile of postmenopausal women.
11/2002	Effects of prednisone withdrawal on the new metabolic triad in cyclosporine-treated kidney transplant patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean Bergeron Research Topics

Disease

28	Insulin Resistance 10/2019 - 03/2004
17	Cardiovascular Diseases (Cardiovascular Disease) 01/2024 - 11/2002
17	Dyslipidemias (Dyslipidemia) 12/2023 - 01/2003
17	Abdominal Obesity 01/2020 - 02/2002
15	Metabolic Syndrome (Dysmetabolic Syndrome X) 12/2014 - 04/2003
14	Type 2 Diabetes Mellitus (MODY) 11/2019 - 01/2006
13	Obesity 10/2019 - 06/2002
12	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 09/2022 - 02/2002
11	Hypertriglyceridemia 01/2023 - 07/2002
8	Homozygous Familial Hypercholesterolemia 01/2024 - 08/2016
8	Atherosclerosis 10/2019 - 11/2002
8	Coronary Disease (Coronary Heart Disease) 04/2015 - 02/2002
7	Inflammation (Inflammations) 05/2022 - 10/2005
6	Hypertriglyceridemic Waist 08/2012 - 07/2002
6	Coronary Artery Disease (Coronary Atherosclerosis) 01/2012 - 07/2002
5	Hyperlipidemias (Hyperlipidemia) 12/2023 - 11/2003
5	Overweight 02/2013 - 10/2006
5	Hyperinsulinism (Hyperinsulinemia) 08/2012 - 02/2002
5	Body Weight (Weight, Body) 10/2005 - 11/2002
4	Hyperlipoproteinemia Type I (Lipoprotein Lipase Deficiency, Familial) 01/2023 - 06/2009
4	Xanthomatosis (Xanthoma) 01/2022 - 01/2018
4	Injection Site Reaction 01/2019 - 07/2012
4	Hypertension (High Blood Pressure) 11/2016 - 12/2004
3	Myocardial Infarction 01/2024 - 04/2010
3	Morbid Obesity 05/2022 - 07/2007
3	Hypercholesterolemia 11/2019 - 03/2003
2	Skeletal Abnormalities Mandibular Hypoplasia Auditory Canal Atresia Short Stature 12/2023 - 01/2023
2	Pancreatitis 01/2023 - 01/2019
2	Cognitive Dysfunction 09/2022 - 01/2016
2	Vitamin D Deficiency 01/2020 - 11/2016
2	Inborn Genetic Diseases (Disease, Hereditary) 01/2019 - 01/2018
2	Muscular Diseases (Myopathy) 01/2016 - 12/2015
2	Myotoxicity 12/2015 - 12/2014
2	Glucose Intolerance 11/2009 - 09/2007
2	Myocardial Ischemia (Ischemic Heart Diseases) 10/2007 - 10/2005
2	Hyperlipoproteinemia Type III (Broad Beta Disease) 08/2007 - 09/2004
1	Stroke (Strokes) 01/2024
1	Lipid Metabolism Disorders (Metabolism Disorders, Lipid) 01/2024
1	Headache (Headaches) 10/2022
1	Appendicitis 10/2022
1	Anorexia Nervosa 10/2022
1	Peritonitis 10/2022

Drug/Important Bio-Agent (IBA)

33	Triglycerides (Triacylglycerol)IBA 01/2023 - 02/2002
29	oxidized low density lipoproteinIBA 01/2024 - 02/2002
21	LipidsIBA 01/2024 - 01/2003
18	Glucose (Dextrose)FDA LinkGeneric 10/2019 - 03/2005
18	Lipoproteins (Lipoprotein)IBA 02/2018 - 02/2002
17	HDL CholesterolIBA 10/2018 - 02/2002
14	LDL CholesterolIBA 03/2024 - 10/2007
14	Insulin (Novolin)FDA Link 01/2018 - 07/2002
14	ApolipoproteinsIBA 06/2017 - 07/2002
12	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2023 - 03/2003
11	C-Reactive ProteinIBA 01/2018 - 03/2003
10	LDL Lipoproteins (beta Lipoproteins)IBA 01/2022 - 02/2002
10	CholesterolIBA 10/2018 - 02/2002
9	Apolipoproteins B (ApoB)IBA 01/2019 - 02/2002
8	Interleukin-6 (Interleukin 6)IBA 01/2018 - 01/2003
7	LDL Receptors (LDL Receptor)IBA 01/2022 - 02/2002
7	HDL LipoproteinsIBA 10/2018 - 06/2002
7	Adenosine Triphosphate (ATP)IBA 12/2014 - 01/2006
6	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 01/2023 - 06/2002
6	Biomarkers (Surrogate Marker)IBA 05/2022 - 07/2007
5	Vitamin D FDA LinkGeneric 12/2023 - 06/2015
5	evolocumabIBA 12/2023 - 10/2020
5	alirocumabIBA 11/2019 - 07/2012
5	Proteins (Proteins, Gene)FDA Link 07/2018 - 03/2003
4	hydroxide ionIBA 01/2020 - 06/2015
4	AdiponectinIBA 01/2018 - 02/2005
4	Apolipoprotein B-48IBA 06/2017 - 12/2003
4	Apolipoprotein B-100 (Apo B 100)IBA 02/2008 - 12/2003
3	Messenger RNA (mRNA)IBA 02/2018 - 04/2010
3	Dextran SulfateIBA 02/2018 - 08/2016
3	Oxidoreductases (Dehydrogenase)IBA 12/2014 - 02/2008
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2010 - 10/2006
3	Atorvastatin (Lipitor)FDA Link 03/2008 - 03/2003
3	Fibrinogen (Factor I)FDA Link 10/2005 - 03/2002
2	Proprotein Convertase 9IBA 06/2022 - 10/2014
2	LeptinIBA 05/2022 - 01/2020
2	Plasminogen Activator Inhibitor 1IBA 05/2022 - 04/2010
2	C-PeptideIBA 09/2019 - 06/2015
2	25-hydroxyvitamin DIBA 09/2019 - 06/2015
2	Insulin-Like Growth Factor Binding Protein 2IBA 01/2019 - 12/2014
2	HDL-triglycerideIBA 01/2018 - 08/2008
2	Lipoprotein(a)IBA 01/2018 - 03/2002
2	Cholesterol Ester Transfer ProteinsIBA 05/2015 - 06/2004
2	Nonesterified Fatty Acids (NEFA)IBA 10/2013 - 02/2009
2	Fenofibrate (CiL)FDA LinkGeneric 03/2008 - 02/2008
2	Fibric Acids (Fibrates)IBA 03/2008 - 02/2008
2	VLDL LipoproteinsIBA 08/2007 - 02/2004
2	Apolipoprotein A-I (Apolipoprotein A1)IBA 02/2007 - 01/2007
2	Dietary Fats (Dietary Fat)IBA 06/2006 - 03/2004
2	Lipase (Acid Lipase)FDA Link 07/2005 - 01/2003
2	Simvastatin (Zocor)FDA LinkGeneric 05/2004 - 02/2002
2	Fatty Acids (Saturated Fatty Acids)IBA 03/2004 - 03/2003
2	Apolipoproteins E (ApoE)IBA 01/2004 - 02/2002
1	omega-Chloroacetophenone (Mace)IBA 01/2024
1	AngiopoietinsIBA 01/2023
1	evinacumabIBA 01/2023

Therapy/Procedure

9	Therapeutics 01/2024 - 11/2002
4	Blood Component Removal (Apheresis) 02/2018 - 08/2016